topic

1065 A replication-defective, HSV-1-based gene therapy for localized delivery of combinatorial Interleukins-12 and -2 for the treatment of cutaneous malignancies
Dana Previte, Mary Jane Duermeyer, Jorge Guzman Lepe, Trevor Parry, Suma Krishnan

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A1172; DOI: 10.1136/jitc-2023-SITC2023.1065
1066 Localized airway delivery of Interleukins-12 and -2 via inhalation of a replication-defective HSV-1-based therapy for the treatment of primary and secondary lung tumors
Dana Previte, Mary Jane Duermeyer, Jorge Guzman Lepe, Trevor Parry, Suma Krishnan

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A1173; DOI: 10.1136/jitc-2023-SITC2023.1066
1067 A three stage immune targeted immuno-cytokine platform that delivers inflammatory signals to the tumor microenvironment
Brian Rabinovich, Xueyuan Zhou, Jeffrey Takimoto, Nikhita Khanna, Sunny Yoon, Evren Alici

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A1174; DOI: 10.1136/jitc-2023-SITC2023.1067
1068 Evaluation of the innate and adaptive immune modulatory properties and anti-tumor activity of CD38-targeted interferon alpha
James F Sampson, Hong Zhang, Tomoya Hara, Dong Mei Zhang, Adam J Hinthorne, Sabrina C Collins, Michael D Curley

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A1175; DOI: 10.1136/jitc-2023-SITC2023.1068
1069 IL-12 mRNA monotherapy is effective in murine tumors resistant to checkpoint inhibition
Sreevidya Santha, Jayalakshmi Lakshmipathi, Man Li, Yuping Qian, Nadia Luheshi, Katerina Politi, Marcus Bosenberg, Jim Eyles, Viswanathan Muthusamy

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A1176; DOI: 10.1136/jitc-2023-SITC2023.1069
1070 ‘Decoy-resistant’ IL-18 in combination with CTLA-4 blockade enhances anti-tumor efficacy in preclinical models of renal cell carcinoma
David A Schoenfeld, Dijana Djureinovic, Lin Zhang, Jacqueline Mann, John Huck, Lucia Jilaveanu, Aaron M Ring, Harriet Kluger

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A1177-A1179; DOI: 10.1136/jitc-2023-SITC2023.1070
1071 Characterization of a tumor-targeting and activatable T-MASK platform to enhance tumor accumulation and tolerability of potent immune modulators
Aanchal Sharma, Rosemina Merchant, Minh D To, Fahar Merchant

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A1180; DOI: 10.1136/jitc-2023-SITC2023.1071
1072 GI-108, a novel bispecific fusion protein augments anti-tumor immunity by alleviating immunosuppressive adenosine pathway in CD8⁺ T cells
Kayoung Shin, Min Park, Seoho Kim, Haejong Lee, Yuseong Lee, Jongil Kim, Suyoun Park, Jisoo Kim, Eunjin Lee, Sanghee Lee, Kyungwha Lee, Chong Woo Park, Young Min Oh, Wonjae Lee, Danbee Ha, Yaein Amy Shim, Young-Gyu Cho, Young Jun Koh, Kookhwan Kim, Myoung Ho Jang

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A1181; DOI: 10.1136/jitc-2023-SITC2023.1072
1073 A phase 1, first-in-human, open-label study evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of PRJ1–3024in subjects with advanced solid tumors
Alexander Starodub, Jason Henry, Andrae Vandross, Cesar Perez, Alexander I Spira, Yang Xu, Yuping Li, Xuebin Liao

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A1182; DOI: 10.1136/jitc-2023-SITC2023.1073
1074 PK/RO modeling of WTX-124, a tumor-activated IL-2 prodrug, highlights the potential for a substantially improved therapeutic index compared to other IL-2 molecules
Kulandayan K Subramanian, Sameer Chopra, Kristin Morris, Christopher J Nirschl, Celesztina Domonkos, Kyriakos Economides, Andres Salmeron, Cynthia Seidel-Dugan, Randi Isaacs, Daniel J Hicklin

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A1183; DOI: 10.1136/jitc-2023-SITC2023.1074

Main menu

topic

Pages

Log in using your username and password

Main menu

Log in using your username and password

You are here

topic

Pages